Methods and compositions for treatment of immune dysfunction disorders
AssigneeAPC, Inc.
InventorsJoy Campbell, Ronald E. Strohbehn, Eric M. Weaver, Barton S. Borg, Louis E. Russell, Francisco Javier Polo Pozo, John D. Arthington, James D. Quigley, III
Life of this patent
Estimating the term…
Abstract
Methods and compositions are disclosed for modulating the immune system of animals. Applicant has identified that oral administration of immunoglubulin or plasma fractions purified from animal serum can modulate serum IgG and/or TNF-α levels for treatment of autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans.
Claims4
A method of treating chronic immune stimulation in a human, comprising orally administering to said human an effective treatment amount of a non-specific immunoglobulin concentrate derived from pig, bovine, ovine, poultry, equine or goat plasma so that serum IgG is lowered in the human, wherein the immunoglobulin concentrate contains approximately 35-50% IgG and wherein the human is afflicted with a condition characterized by chronic immune stimulation.
A method of treating Crohn's disease in a human, comprising orally administering to said human an effective treatment amount of a non-specific immunoglobulin concentrate derived from pig, bovine, ovine, poultry, equine or goat plasma so that serum IgG is lowered in the human, wherein the immunoglobulin concentrate contains approximately 35-50% IgG and wherein the human is afflicted with Crohn's disease.
A method of treating rheumatoid arthritis in a human, comprising orally administering to said human an effective treatment amount of a non-specific immunoglobulin concentrate derived from pig, bovine, ovine, poultry, equine or goat plasma so that serum IgG is lowered in the human, wherein the immunoglobulin concentrate contains approximately 35-50% IgG and wherein the human is afflicted with rheumatoid arthritis.
A method of treating Human Immunodeficiency Virus (HIV) in a human, comprising orally administering to said human an effective treatment amount of a non-specific immunoglobulin concentrate derived from pig, bovine, ovine, poultry, equine or goat plasma so that serum IgG is lowered in the human, wherein the immunoglobulin concentrate contains approximately 35-50% IgG and wherein the human is afflicted with Human Immunodeficiency Virus (HIV).
Dependencies are inferred from the claim text.